|Bid||13.24 x 800|
|Ask||13.26 x 900|
|Day's Range||12.84 - 13.29|
|52 Week Range||7.52 - 27.15|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.63|
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to its GB001 and GB002 programs at the American Thoracic Society 2020 Virtual Conference, which takes place from August 5th through 8th.
If you want to know who really controls Gossamer Bio, Inc. (NASDAQ:GOSS), then you'll have to look at the makeup of...
As of late, it has definitely been a great time to be an investor in Gossamer Bio.